source
- BioMarin signs up to $475 million licensing deal for new Fabry disease enzyme therapyBioMarin announced a licensing agreement to acquire rights to a long‑acting enzyme replacement therapy candidate for Fabry disease, paying $70 million upfront and up to $405 million in development…
- Gilead places partial clinical hold on two KITE-753 CAR-T trials in diffuse large B-cell lymphomaGilead announced on its third-quarter earnings call that it has placed a partial clinical hold on two CAR-T trials for KITE-753 targeting diffuse large B-cell lymphoma (DLBCL). The hold affects th…